Buparlisib (BKM120)

For research use only. Not for use in humans.

目录号：S2247 别名： NVP-BKM120 中文名称：布帕尼西

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2227.95	现货
5mg	RMB 1400.12	现货
10mg	RMB 2607.65	现货
50mg	RMB 7928.28	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Buparlisib (BKM120)发表文献203篇：

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Immunol, 2020, 21(4):442-454

PubMed: 32152508 ( click the link to review the publication )

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Cancer Discov, 2017, 7(9):1018-1029

PubMed: 28619981 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Cell, 2012, 27;149(3):656-70.

PubMed: 22541435 ( click the link to review the publication )

Nat Med, 2012, 18(6):892-901

PubMed: 22610277 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1920

PubMed: 33772001 ( click the link to review the publication )

Theranostics, 2021, 11(8):3552-3564

PubMed: 33664847 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):108

PubMed: 33479203 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):400

PubMed: 33854046 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):24

PubMed: 33407478 ( click the link to review the publication )

Cell Biol Int, 2021, 10.1002/cbin.11557

PubMed: 33501756 ( click the link to review the publication )
Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2500

PubMed: 32899250 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01074-2

PubMed: 32963347 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16208

PubMed: 33004905 ( click the link to review the publication )

Front Neurosci, 2020, 2;14:223

PubMed: 32300287 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Genes Cancer, 2020, 11(3-4):106-121

PubMed: 33488949 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):126-144

PubMed: 32123862 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Small GTPases, 2020, 10.1080/21541248

PubMed: 32043900 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):226-237

PubMed: 30692625 ( click the link to review the publication )
Nat Commun, 2019, 10(1):259

PubMed: 30651547 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0556-z

PubMed: 31462739 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(8):2380-2394

PubMed: 31149050 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0422-6

PubMed: 31570855 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E37

PubMed: 30609754 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Mol Ther Oncolytics, 2019, 13:58-66

PubMed: 31016228 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):834-844

PubMed: 30787173 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2774-2788

PubMed: 31911861 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):10907-10917

PubMed: 30536897 ( click the link to review the publication )

Front Oncol, 2019, 0.87569444444

PubMed: 31428587 ( click the link to review the publication )

Front Oncol, 2019, 9:1119

PubMed: 31750239 ( click the link to review the publication )

Eur J Immunol, 2019, doi: 101002/eji201948241

PubMed: 31621069 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )
Biochem J, 2019, 476(23):3583-3593

PubMed: 31738383 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Chem Biol Interact, 2019, 302:101-107

PubMed: 30703376 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211

PubMed: 30947576 ( click the link to review the publication )

Int J Hematol, 2019, 110(2):213-227

PubMed: 31129802 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 05:31

PubMed: 31552290 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1357

PubMed: 29636477 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(5)

PubMed: 29650805 ( click the link to review the publication )

Cancer Res, 2018, 78(8):2000-2013

PubMed: 29437705 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

Cell Rep, 2018, 24(2):463-478

PubMed: 29996106 ( click the link to review the publication )

Elife, 2018, 7e33718

PubMed: 30475204 ( click the link to review the publication )

Int J Cancer, 2018, 143(5):1188-1201

PubMed: 29582409 ( click the link to review the publication )
Int J Cancer, 2018, 142(9):1926-1937

PubMed: 29210065 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29535262 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2049-2059

PubMed: 29970482 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10784

PubMed: 30018387 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3223-3234

PubMed: 30272286 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3321-3328

PubMed: 29435074 ( click the link to review the publication )

NPJ Breast Cancer, 2018, 4:36

PubMed: 30456298 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8:15021

PubMed: 28443643 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(41):E8628-E8636

PubMed: 28973876 ( click the link to review the publication )

Cancer Res, 2017, 77(16):4448-4459

PubMed: 28652248 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(10):1864-1888

PubMed: 28794006 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

SLAS Discov, 2017, 22(8):974-984

PubMed: 28644734 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52474-52487

PubMed: 28881745 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(13):21806-21817

PubMed: 28423521 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(44):76935-76948

PubMed: 29100359 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1324-1335

PubMed: 27870828 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

PLoS Biol, 2016, 14(11):e1002581

PubMed: 27880766 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Transl Med, 2016, 14:56

PubMed: 26912358 ( click the link to review the publication )
Int J Biochem Cell Biol, 2016, 79:308-317

PubMed: 27599915 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Oncotarget, 2016, 7(41):67277-67287

PubMed: 27572309 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )

J Clin Invest, 2015, 125(12):4559-71

PubMed: 26529251 ( click the link to review the publication )

Genes Dev, 2015, 29(16):1677-82

PubMed: 26272820 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Glia, 2015, 63(10):1850-9

PubMed: 25944104 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1194-209

PubMed: 26293922 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Biomed Pharmacother, 2015, 75:40-50

PubMed: 26463630 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Cell Signal, 2015, 27(12):2389-400

PubMed: 26363466 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )
Int Immunopharmacol, 2015, 28(1):675-85

PubMed: 26256696 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10399-414

PubMed: 25871383 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )
Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5459-72

PubMed: 23796563 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

Cell Commun Signal, 2013, 11(1):3

PubMed: 23311350 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

BKM120是可用于口服的生物有效的PI3K抑制剂。

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	点击更多
52 nM	116 nM	166 nM	262 nM	2.4 μM	点击更多

体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。^[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。^[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。^[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
glioma cell lines	NVjrZVQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIf2THA4Omh?		Mmm3TWM2OD1zLUNOwG0>	Ml\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyNkWwPFAoRjJ{ME[1NFgxRC:jPh?=
U87	NX3sc3MzSXCxcITvd4l{KEG\|c3H5	M4XsNFLPxE1?	NH;nemk4Omh?		NYfHe4pQcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM>	NI\OSYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC2OVA5OCd-MkKwOlUxQDB:L3G+
SNU-601	M{ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M335S\|czcA>?	NYWy[HRKTE2VTx?=	MXHJR\|UxRTBwOEG2xtExNjB4M988US=>	NHzHdGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-1	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX\BVY1vPzKq	NF3KW5NFVVOR	NEn4No1KSzVyPUGuNFgzyrFyLkCyPO69VQ>?	MkHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-668	NVrHR5pxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHjRcHQ4Omh?	MYTEUXNQ	Ml3LTWM2OD1zLkW3PeKyOC5yN{VOwG0>	NYjTUWdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
AGS	M1PHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV;zVY86PzKq	NVT0XW1[TE2VTx?=	MVnJR\|UxRTFwN{G0xtExNjFzN988US=>	MnXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-216	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGrxXVA4Omh?	NF7UcotFVVOR	M3fURWlEPTB;Mj62PVLDuTBwMEiy{txO	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-5	M2HEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUnGTW4zPzKq	M2HqNGROW09?	NFzo[lBKSzVyPUGuN\|UyyrFyLkC5Ne69VQ>?	NFvmdHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-638	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkDrO\|Jp	MmjSSG1UVw>?	M{DGVmlEPTB;Mj6yPFLDuTBwMEWz{txO	NXjHdIVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-16	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LPWVczcA>?	NIi0[XVFVVOR	M1jzSGlEPTB;MT61O\|PDuTBwMECx{txO	M4TBWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-484	M2TLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEHHWGI4Omh?	NXS3clBDTE2VTx?=	M2LqbGlEPTB;MT63NljDuTBwMES1{txO	MmTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-620	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIi1PVA4Omh?	NYnRXIlCTE2VTx?=	NIrO[YJKSzVyPUKuPVM6yrFyLkCwNe69VQ>?	MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-719	MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2DTV\|czcA>?	M1HSSWROW09?	MonSTWM2OD1\|LkCzO:KyOC5yM{NOwG0>	NHLiUWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
MM cell lines	M2HofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjU[HEyOM7:TR?=	M1TiVFI1cA>?	Mn;DSG1UVw>?	M4LtXGlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>?	M{\lSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC3OFg2Lz5{MkKwO\|Q5PTxxYU6=
ARP-1	MVLBdI9xfG:\|aYOgRZN{[Xl?	NWrCNml{OTEQvF2=	M2XUZlI1cA>?	MkXVSG1UVw>?	M3ThWIlv\HWlZYOgUW0h[2WubDDhdI9xfG:\|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36=	Ml7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MEe0PFUoRjJ{MkC3OFg2RC:jPh?=
colon cancer cell lines	NWXB[Jg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvLOFUxNTFyzszN	M1fXO\|czcA>?	M2rqcmROW09?	NF3NPVdKSzVyPUJOwG0>	M3vtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
gastric cancer cell lines	NEe3WXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\UdlAuOTEQvF2=	Mn7WO\|Jp	MkSzSG1UVw>?	MX3JR\|UxRTJvNd88US=>	NIX5N449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0N\|g2Pyd-MkK1OFM5PTd:L3G+
HCT-116/HT-29/MKN-45	M1HqW2Fxd3C2b4Ppd{BCe3OjeR?=	NGTJWGQz\|ryP	MWG0PIg>		M{HJdpNpcW[2IHnuJGczKHCqYYPl	M17C[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
HT-29 and HCT-116	NFjrUJdE[XOyYYPlJIF{e2G7	NFLCV5I2\|ryP	NHr2eo4zPGh?		NITMNnBqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm=	M1WxdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
PIK3CA-mutant MCF7	M3XRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO\|NvVQ>?	NWTsbm1PPzKq		MXXHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO\|NvVQ>?	NUnSbJNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjdpPkKyOlU{QTZ5PD;hQi=>
PIK3CA-mutant MCF7	MkDvT4lv[XOnIFHzd4F6	M{\pcWlEPTB;MUG0xtE{dk1?	MWm3Nog>		MoLsTWM2OD1zMUVCtVNvVSCrbjDy[YR2[2mwZzDBb5QheGixc4Doc5J6dGG2aX;uJIxmfmWucx?=	NVi4SVBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjdpPkKyOlU{QTZ5PD;hQi=>
MCF7-myr-Akt	NHzqU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLK[4QxT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2=	M2TpPFczcA>?		Mm\VS2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1?	NWrz[IJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjdpPkKyOlU{QTZ5PD;hQi=>
Y1 cell line	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPkNE4y\|ryPL{JOwG0>	M3nRelI1cA>?	NIjte\|ZFVVOR	NV7ZbXo3cW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO=	MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OUK5NFQoRjJ{NkmyPVA1RC:jPh?=
human NSCLC	NUTlbFBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYOwMlUuOs7:TR?=	NIrXZXQ4Omh?		Ml34TWM2OD1zzszN	MlHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEGzPVMoRjJ{N{ixN\|k{RC:jPh?=
human NSCLC	M13pbWtqdmG\|ZTDBd5NigQ>?	NWHN[VNFOc7:TR?=	MX2yOIg>		MmXzbY5pcWKrdIOgeIhmKEGtdD;tWG9TKHOrZ37hcIlv\yCyYYToe4F6KGG2IEPoJIFnfGW{IITy[YF1dWWwdB?=	NXnsNpdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3PFE{QTNpPkKyO\|gyOzl\|PD;hQi=>
JVM2	NIG5fHREgXSxdH;4bYNqfHliYYPzZZk>	MX6wMlIuOjEQvF2=	MYS3Nog>	MVHEUXNQ	NXzGVXBbUUN3ME2wMlnPxE1?	NFvZcIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN\|g3Ozl:L3G+
EHEB	M{SwWGN6fG:2b4jpZ4l1gSCjc4PhfS=>	NVHUcVBlOC5{LUKw{txO	M{jQU\|czcA>?	MYDEUXNQ	NUDRdnIzUUN3ME2wMlfPxE1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|OE[zPUc,OjN{M{i2N\|k9N2F-
MEC2	NWXLfVE3S3m2b4TvfIlkcXS7IHHzd4F6	NWfzbpVxOC5{LUKw{txO	NEDNdIo4Omh?	MojaSG1UVw>?	MUHJR\|UxRTBwN988US=>	NVrTRmpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN\|g3OzlpPkKzNlM5PjN7PD;hQi=>
primary B-CLL lymphocytes	MYHBdI9xfG:\|aYOgRZN{[Xl?	MYnJR\|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m	Mn3KNlRp	NH7CcVNFVVOR	M{j5dGlEPTExvKyz{txOKG[xcjDhcIwheGG2aXXueJM>	NHnxbJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN\|g3Ozl:L3G+
primary B-CLL lymphocytes	NH3wOXRMcW6jc3WgRZN{[Xl?	NVywXGZtUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?=	MmLVNlRp		MmjobY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|OE[zPUc,OjN{M{i2N\|k9N2F-
SK-HEP1	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHQNU0zOM7:TR?=	NEmzN4o4Omh?	NFLCTmFFVVOR	Mn;FTWM2OO,:nEJOwG0>	MoL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{mxN\|YoRjJ\|NEe5NVM3RC:jPh?=
786-0	MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\jWYwyNTJyzszN	M2rBNlczcA>?	MUHEUXNQ	MVXJR\|Ux97zeMd88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5OUGzOkc,OjN2N{mxN\|Y9N2F-
human HCC cell lines	NYXRSJB3S2WubDD2bYFjcWyrdImgZZN{[Xl?	Mlu0NE4xODVvMd88US=>	MYq0PIg>		MWDJR\|UxRTIQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OUm5PUc,OjN2OEm5PVk9N2F-
Huh7	Mn7uT4lv[XOnIFHzd4F6	MX2x{txO	M{PodFQ5cA>?		NGrS[3N{cWewaf-shYNidnSueTDy[YR2[2W\|IIDoc5NxcG:{eXzheIlwdiCxZjDBb5Q>	M3nkTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5PVk6Lz5{M{S4PVk6QTxxYU6=
human NSCLC cell lines	MnzPRZBweHSxc3nzJGF{e2G7	NFfHfGMxNjF{NT20{txO	MnPENlRp	NUTRNIZwTE2VTx?=	NIPXe4dKSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=>	MnnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkK0O\|IoRjJ\|NU[yOFczRC:jPh?=
Primary CLL cells	NVPpT5U4SXCxcITvd4l{KEG\|c3H5	MVqxMVEx\|ryP	NYf4Rm9IPDiq		MWfpcoR2[2W\|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz	NFjlNXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
Primary CLL cells	MY\LbY5ie2ViQYPzZZk>	MWWy{txO	NXPubVFJOzCvaX6=		MXnk[YNz\WG\|ZXSgVGk{UyCjY4Tpeol1gQ>?	NWT5[HkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVA5ODdpPkKzPFUxQDB5PD;hQi=>
Primary CLL cells	MUDDfZRwfG:6aXOgRZN{[Xl?	MlvaNu69VQ>?	NWrac4dKOjSq		NEXIfI5qdmS3Y3XzJINmdGxiY4n0c5RwgGmlaYT5	MoXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC4NFcoRjJ\|OEWwPFA4RC:jPh?=
LC-1/SQSF	Mlu2SpVv[3Srb36gRZN{[Xl?	NEfqO2U{\|ryP	MnexNlRp	NFjPTFBFVVOR	NF;jbpZl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw>	NYTJZ4c4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PFAxQTNpPkKzPVgxODl\|PD;hQi=>
BCR-ABL	M1KxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PzWlAvOjVvMUFOwG0>	M3PzdFRl		NXnjOFhMe2mpbnnmbYNidnSueTDpcohq[mm2IHPlcIwheHKxbHnm[ZJifGmxbh?=	NHHoRWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFYyOid-MkSyOFQ3OTJ:L3G+
T-ALL	M1PHUWFxd3C2b4Ppd{BCe3OjeR?=	MYXi[ZR4\WWwIEGuOEBidmRiNT6zJI1OKGG2IEK0bEBidmRiMD65JIFv\CB3LkWgcW0h[XRiNEjoJIlvKGSrZn\ldoVvfCClZXzsJIxqdmV?	NGnrdFAzPCCxcjC0PIg>	MWnEUXNQ	MlP4ZYZn\WO2czD0bIUhWEl\|SzDwZZRpf2G7IHnuJHQuSUyOIHPlcIwhdGmwZYO=	NXnr[WZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVA4OzZpPkK0N\|ExPzN4PD;hQi=>
H1975	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3qNE4{NTlwNt88US=>	M4Lse\|czcA>?	Mn7aSG1UVw>?	Mm\LTWM2OD1zLkO4Oe69VQ>?	NYOxfJNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|c5PDZpPkK0N\|M4QDR4PD;hQi=>
H1975	MlrWRZBweHSxc3nzJGF{e2G7	Mn\iNu69VQ>?	NXnW[GF2OjSq	NXvUXoo5TE2VTx?=	M17yfIlv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6	NWO2TnVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|c5PDZpPkK0N\|M4QDR4PD;hQi=>
BON	NW[2cok6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrUNU02\|ryP	Ml3ZO\|Jp		MlPa[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR2M{WyN{c,OjR2NEO1NlM9N2F-
BON	MWTBdI9xfG:\|aYOgRZN{[Xl?	M{T4cVEuPc7:TR?=	NF3DdGwzPGh?		MonjbY5kemWjc3XzJIFxd3C2b4Ppdy=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR2M{WyN{c,OjR2NEO1NlM9N2F-
GBM	MnHDRZBweHSxc3nzJGF{e2G7	MnrmNu69VQ>?	MXS0PIg>	MX;EUXNQ	M3ryTolv\HWlZXSgbIlocGW{IHzleoVteyCxZjDhdI9xfG:\|aYOsJIFv\CCmZXPy[YF{\WRiY3XscEB3cWGkaXzpeJk>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVyMES5Nkc,OjR3MEC0PVI9N2F-
FaDu	NHPqT4dHfW6ldHnvckBCe3OjeR?=	MW[1JO69VQ>?	MlmyNlQhcA>?	NF7mPWRFVVOR	NVfzTlV2WmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44>	M4DKbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOxNVQ4Lz5{NE[zNVE1PzxxYU6=
EMT6	NVHTUXR5TnWwY4Tpc44hSXO\|YYm=	NEfaT3I2KM7:TR?=	NGjvW\|YzPCCq	NUO2UlRHTE2VTx?=	MX7S[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	M3LUWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOxNVQ4Lz5{NE[zNVE1PzxxYU6=
HCT116	M3PrN2Z2dmO2aX;uJGF{e2G7	NYrRNGE1PSEQvF2=	MV6yOEBp	MlztSG1UVw>?	Moe0VoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36=	NXTXeFkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|EyPDdpPkK0OlMyOTR5PD;hQi=>
U87	MofzSpVv[3Srb36gRZN{[Xl?	MVS1JO69VQ>?	M{fTeFI1KGh?	NEfWW5BFVVOR	MWjS[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	M4npeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOxNVQ4Lz5{NE[zNVE1PzxxYU6=
Saos-2	NX\udGxqTnWwY4Tpc44hSXO\|YYm=	MnmxOVAh\|ryP	Mor5OFghcA>?		NXTDPI5tUW6qaXLpeJMh[2WubDDpcpZie2mxbh?=	NGCyTZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63	NVH0V2RUTnWwY4Tpc44hSXO\|YYm=	MUW1NEDPxE1?	MnfoOFghcA>?		MnHCTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>?	NEPMcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1	M2fUeWZ2dmO2aX;uJGF{e2G7	MonEOVAh\|ryP	M3O0WFQ5KGh?		M{fqbWlvcGmkaYTzJINmdGxiaX72ZZNqd25?	NEjseYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
Saos-2	NIGxW4VHfW6ldHnvckBCe3OjeR?=	Mnr6OVAh\|ryP	MVy0PEBp		NV;RS\|djUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	NFvZSII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63	MoDySpVv[3Srb36gRZN{[Xl?	M13vOVUxKM7:TR?=	MX20PEBp		NFrCcFRKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v	NGDzNmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1	NVLGNmV5TnWwY4Tpc44hSXO\|YYm=	MkPEOVAh\|ryP	NXTKVJZRPDhiaB?=		MUTJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO\|aX;u	MnTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
Saos-2	M1LESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[5OFUxKM7:TR?=	M1\jRVQ5KGh?		Ml62TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	NYfvWW8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
MG-63	NFfFd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi1T3hlPTBizszN	NIP1[Ww1QCCq		NUjORoRqUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	NVTtNodVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
SJSA-1	NVOwTYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnrOVAh\|ryP	Mn\zOFghcA>?		NFXPd4xKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
LN18	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfLXJgzOCEQvF2=	M1;FU\|czKGh?	NGTnT4hFVVOR	M4LmfWlEPTB:NTFOwG0>	NVLvdJRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
LN229	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6yNEDPxE1?	M1zGVVczKGh?	NUPBR2ZJTE2VTx?=	M1roTGlEPTB:NTFOwG0>	Mkn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
LNZ308	M3fJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVGyNEDPxE1?	MUK3NkBp	MofwSG1UVw>?	M3\Pe2lEPTB:NTFOwG0>	NULFTVRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
T98G	M1zlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUCyNEDPxE1?	NELTRYY4OiCq	NEfvflZFVVOR	NXLsbmxsUUN3MEy1JO69VQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
U87	NWj0ZmQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXmyNEDPxE1?	NUjOfYxnPzJiaB?=	MnHwSG1UVw>?	M1\y[mlEPTB:NTFOwG0>	NHrRRYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LN18	NYS3[VR5TnWwY4Tpc44hSXO\|YYm=	MWi1JO69VQ>?	MmLkNlQhcA>?	NITMcVZFVVOR	MnTZTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>?	NYG2N3F1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
LNZ308	M{\UN2Z2dmO2aX;uJGF{e2G7	M3ThUVUh\|ryP	NFH3UIYzPCCq	NInB[5hFVVOR	M{O5TGlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
MDA-MB-175	M{jU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWexJO69VQ>?	M{XpUlUh\A>?	NGrPWW9FVVOR	NWjtdoVqUUN3MEyxJO69VQ>?	NGjQTWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MDA-MB-134	NHS4e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO1WlA{OSEQvF2=	MYi1JIQ>	NEPKTI1FVVOR	MUPJR\|UxRDFizszN	NX7sTJJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1500	NXq2XoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWxJO69VQ>?	MnjrOUBl	NEjY[\|dFVVOR	NY\OTWFxUUN3MEyxJO69VQ>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
EFM-19	NGnTeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zZb\|Eh\|ryP	NIH1SlQ2KGR?	MkK0SG1UVw>?	M1HHdmlEPTB:MTFOwG0>	NY\KcmdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
ZR-75-30	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTjVpIyKM7:TR?=	MUO1JIQ>	M4e2RWROW09?	NWLXNWVvUUN3MEyxJO69VQ>?	NUPWb4VZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-361	MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmL2NUDPxE1?	NYfNOZhrPSCm	NFfQbnBFVVOR	NY\YR5F4UUN3MEyxJO69VQ>?	Mor4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
T-47D	NFfTTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnTNm0yKM7:TR?=	NEHvNnQ2KGR?	NVHCZmcxTE2VTx?=	MlfJTWM2ODxzIN88US=>	M4X5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
SK-BR-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYWxJO69VQ>?	NVfVU\|BtPSCm	M3HtVGROW09?	NI\qfmdKSzVyPEGg{txO	NVvPfIx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
UACC-732	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXexJO69VQ>?	M2Xhd\|Uh\A>?	NGTvNoJFVVOR	NFTYc5VKSzVyPEGg{txO	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
BT-474	NGDoSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTBOIRROSEQvF2=	Moj5OUBl	NF6ye5NFVVOR	NILPXVJKSzVyPEGg{txO	NYmxfVBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC202	NHvCTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:xJO69VQ>?	M4q3flUh\A>?	MoS2SG1UVw>?	MlHsTWM2ODxzIN88US=>	NEDaUpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MCF7	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrpUFEyKM7:TR?=	M4n3SVUh\A>?	NWX4dmRKTE2VTx?=	Mkm0TWM2ODxzIN88US=>	NXPpOGNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-415	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfJdG1HOSEQvF2=	M1:4NlUh\A>?	Mo\wSG1UVw>?	NU\NNGp5UUN3MEyxJO69VQ>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-453	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVexJO69VQ>?	MmLjOUBl	M3WzXGROW09?	MUHJR\|UxRDFizszN	MojoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
ZR-75-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fTXlEh\|ryP	NWHIUWVxPSCm	NGLpcnNFVVOR	M{CwfmlEPTB:MTFOwG0>	NFnhco09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC38	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj6NZgyKM7:TR?=	M4fpfFUh\A>?	MUXEUXNQ	M2fkZWlEPTB:MTFOwG0>	NYT6d21ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1419	M1\KN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\FNUDPxE1?	MVS1JIQ>	M17UbGROW09?	MkHITWM2ODxzIN88US=>	NGPa[ZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
UACC-812	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTKNUDPxE1?	MVO1JIQ>	NHTFZXZFVVOR	MlzETWM2ODxzIN88US=>	M1LMflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
HCC1187	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEO4ZYEyKM7:TR?=	M{H1UVUh\A>?	NF\UWoZFVVOR	MXjJR\|UxRDFizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
KPL-1	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXqxJO69VQ>?	M3GzblUh\A>?	NYq5VGRyTE2VTx?=	MnHlTWM2ODxzIN88US=>	M2T1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
SUM-225	M1\KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYOxJO69VQ>?	M{O1[lUh\A>?	M3\UPWROW09?	NELsd2NKSzVyPEGg{txO	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
EFM-192A	Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnYeo4yKM7:TR?=	MlzGOUBl	MVXEUXNQ	MXHJR\|UxRDFizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
JIMT-1	NV7FRW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1G5SFEh\|ryP	MXW1JIQ>	MnLqSG1UVw>?	MX;JR\|UxRDFizszN	NIPtdXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1143	NHO2S2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWxJO69VQ>?	MXO1JIQ>	NF:xT5FFVVOR	M{XINGlEPTB:MTFOwG0>	Mo\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC2218	NFq4TmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\y[XUyKM7:TR?=	M33lXlUh\A>?	MXXEUXNQ	MmLWTWM2ODxzIN88US=>	NFnFTHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MDA-MB-468	M325[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzyTpVoOSEQvF2=	NIfZbFM2KGR?	MkXnSG1UVw>?	M1PEfmlEPTB:MTFOwG0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
BT-20	NES2OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknYNUDPxE1?	MVO1JIQ>	MXvEUXNQ	NFHVcpZKSzVyPEGg{txO	MlrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-435	NEHuUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\iWVEh\|ryP	MlnXOUBl	NIO5dZhFVVOR	MknNTWM2ODxzIN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
BT-549	NECybGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHQNUDPxE1?	NImyfmk2KGR?	NVe2e3puTE2VTx?=	NXjlT2g6UUN3MEyxJO69VQ>?	NXrub3ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1806	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGxJO69VQ>?	MXq1JIQ>	NFzuV4lFVVOR	MUDJR\|UxRDFizszN	NI\hemQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1937	M370Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfESVYyKM7:TR?=	M4e1[VUh\A>?	M{\j[WROW09?	MUnJR\|UxRDFizszN	MmCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
Hs578T	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTTbGYyKM7:TR?=	MVK1JIQ>	M3G2bmROW09?	NUHpSVFCUUN3MEyxJO69VQ>?	NGrqUVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MCF7	MoLGR5l1d3SxeHnjJGF{e2G7		M3TQTFczKGh?	NEXXdY1FVVOR	M{LBVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFiRUW0OWshdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFE2QCEQvF2=	NUHxfmlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
DU145	M37Ue2N6fG:2b4jpZ{BCe3OjeR?=		MW[3NkBp	NIDCc2VFVVOR	M2HEOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGW6cILld5NqdmdiTFvCNUBufXSjboSge4l1cCCJSUWwJI9nKDBwMECwOFM2KM7:TR?=	M{TodlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
A2780	NFvX[\|dEgXSxdH;4bYMhSXO\|YYm=		MWq3NkBp	NUf6eZlGTE2VTx?=	NU\ibnZXS3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjN3IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
U87MG	MWfDfZRwfG:6aXOgRZN{[Xl?		M4P5N\|czKGh?	MUnEUXNQ	MnHmR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?=	NVX0XFlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
A2780	MYPGeY5kfGmxbjDBd5NigQ>?		NHzsNpEyKGh?	M3X2WWROW09?	MVXJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>?	M4HYVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
DU145	M1;2XmZ2dmO2aX;uJGF{e2G7		NIOz[GYyKGh?	Mn\qSG1UVw>?	MVPJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gSHUyPDViY3XscJMhcGG{Yn;ybY5oKEyNQkGgcZV1[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEezJO69VQ>?	M{PjTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
A2780	MV3GeY5kfGmxbjDBd5NigQ>?		MmKzNUBp	NXHmfXZoTE2VTx?=	M4H1fGlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO\|Qh\|ryP	MofYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
MCF7	NHPJcYdHfW6ldHnvckBCe3OjeR?=		NUPlUnNiOSCq	NHzBXJJFVVOR	MlHHTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO	MoH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
U87MG	NUTRXZRPTnWwY4Tpc44hSXO\|YYm=		MlroNUBp	NUK5dG1FTE2VTx?=	NWq1V5RJUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?=	Ml7MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780	M1vVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkDUO\|IhcA>?	M1facGROW09?	NVjVV5dpTUN3ME2wMlUzKM7:TR?=	NWDlXHpORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
Huh7	M3n1WmZ2dmO2aX;uJGF{e2G7	NVHCOoNoOSEQvF2=	NEj0dZEyKGh?	MVLEUXNQ	NXq5XIRjUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S=	NUnqW4tQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFQ1ODNpPkK1NFA1PDB\|PD;hQi=>
BNL	NVvwTIpITnWwY4Tpc44hSXO\|YYm=	MXGxJO69VQ>?	M3f2UFEhcA>?	MkHpSG1UVw>?	Mk\RTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3	MoLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMES0NFMoRjJ3MEC0OFA{RC:jPh?=
BON-1	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;LOVAxKG6P	MXqxNEBl	MUHEUXNQ	M2SzUWlvcGmkaYTzJINmdGxiZ4Lve5Rp	Ml\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
BON-1	NIqydGhHfW6ldHnvckBCe3OjeR?=	MYG1NFAhdk1?	Mn[0OEBp	MkLISG1UVw>?	NHT4SGNKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez	Ml\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
QGP-1	NV\GeIU2TnWwY4Tpc44hSXO\|YYm=	NEi4bmg2ODBibl2=	NEn6W5M1KGh?	M4\yO2ROW09?	M3z0b2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O=	M{\BfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
HCT-15	MWLBdI91d3OrczDBd5NigQ>?	MYixNEDPxE1?	NFXseow1QCCq	MXjEUXNQ	MYXJcoR2[2W\|IHHwc5B1d3OrczDpckBJS1RvMUWgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>?	NEi1Uos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
HCT-116	M{PJO2Fxd3Sxc3nzJGF{e2G7	MVGxNEDPxE1?	MnjHOFghcA>?	MWfEUXNQ	MkGzTY5lfWOnczDhdI9xfG:\|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	NUTndZBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
NCI-H460	M4jrbGFxd3Sxc3nzJGF{e2G7	MU[xNEDPxE1?	MmHmOFghcA>?	M3LC[2ROW09?	MmG2TY5lfWOnczDhdI9xfG:\|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
SKOV-3	NGf3cppCeG:2b4Ppd{BCe3OjeR?=	MYCxNEDPxE1?	NXHododJPDhiaB?=	MkD3SG1UVw>?	NYHZO\|BpUW6mdXPld{BieG:ydH;zbZMhcW5iU1vPWk0{KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36=	NHHrNmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
BSY-1	NXnBVpIxSXCxdH;zbZMhSXO\|YYm=	MmT2NVAh\|ryP	NYD6R4RMPDhiaB?=	NVi5U\|dGTE2VTx?=	NYnQPJUzUW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	NXLDRmJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
MKN-1	NXS4Rmo4SXCxdH;zbZMhSXO\|YYm=	NVfadmFROTBizszN	MU[0PEBp	NVi2eYtNTE2VTx?=	MXfJcoR2[2W\|IHHwc5B1d3OrczDpckBOU05vMTDj[YxteyCqYYLic5VzcW6pIGDJT\|NESSCqb4TzdI91KG23dHH0bY9v	MnH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
NCI-H522	M{fVfGFxd3Sxc3nzJGF{e2G7	MUCxNEDPxE1?	MXO0PEBp	NXL0ZmJRTE2VTx?=	MUDJcoR2[2W\|IHHwc5B1d3Orcx?=	MmTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
OVCAR-3	NIjGN2FCeG:2b4Ppd{BCe3OjeR?=	M{S5fVExKM7:TR?=	M2fLUFQ5KGh?	MoXVSG1UVw>?	MVnJcoR2[2W\|IHHwc5B1d3Orcx?=	NV7RTnFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
HBC-5	M3zYRmFxd3Sxc3nzJGF{e2G7	MkHaNVAh\|ryP	NIK3[o01QCCq	M1[1NGROW09?	MVzJcoR2[2W\|IHHwc5B1d3Orcx?=	NY\nN3pxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
RXF-631L	MYPBdI91d3OrczDBd5NigQ>?	NH;QN24yOCEQvF2=	M1XN[\|Q5KGh?	M{DxdWROW09?	NYDHe4xiUW6mdXPld{BieG:ydH;zbZM>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
MKN-45	NGfqRXpCeG:2b4Ppd{BCe3OjeR?=	NHeyV4syOCEQvF2=	M32xW\|Q5KGh?	MUPEUXNQ	Mor3TY5lfWOnczDhdI9xfG:\|aYO=	NWWw[YFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
LNCaP	MYHGeY5kfGmxbjDBd5NigQ>?	M4TnVFEh\|ryP			M3fscnN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy\|	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MEe5PUc,OjV\|NkC3PVk9N2F-
LNCaP95	NFTjR4tHfW6ldHnvckBCe3OjeR?=	M1;x[\|Eh\|ryP			NFPEPZdUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MEe5PUc,OjV\|NkC3PVk9N2F-
A549	MV7GeY5kfGmxbjDBd5NigQ>?	NGTQV\|E2ODBibl2=	MVi0PEBp	MmK5SG1UVw>?	NYXrWFNOUW6qaXLpeJMhSWu2IHHjeIl3[XSrb36=	MlTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{eyPVkoRjJ3OUO3Nlk6RC:jPh?=
A549	MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7mWJE6OSEQvF2=	NHXmOZM4OiCq	NIf2fWpFVVOR	MVXJcohq[mm2czDj[YxtKGe{b4f0bC=>	M4TMOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO\|I6QTxxYU6=
H522	NI\VSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3j4PVEh\|ryP	Mon5O\|IhcA>?	MVjEUXNQ	M{f4UWlvcGmkaYTzJINmdGxiZ4Lve5Rp	NWTLZpJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|czQTlpPkK1PVM4Ojl7PD;hQi=>
SKMES-1	MXrDfZRwfG:6aXOgRZN{[Xl?	NGD5TmQyKM7:TR?=	M2XaVVczKGh?		MWnJcoR2[2W\|IHPlcIwh\GWjdHi=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjBzM{OxPEc,OjZyMUOzNVg9N2F-
H596	M4SycWZ2dmO2aX;uJGF{e2G7	MoPsNUDPxE1?			MlPhTY1x[Wm{czDj[YxtKG2rZ4LheIlwdg>?	NEDTRpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCxN\|MyQCd-Mk[wNVM{OTh:L3G+
HCC2450	NF:2[5lHfW6ldHnvckBCe3OjeR?=	MmPpNUDPxE1?			MmrMTY1x[Wm{czDj[YxtKGmwdnHzbY9v	M3nBflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEGzN\|E5Lz5{NkCxN\|MyQDxxYU6=
HCT116	M4rJS2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXzTb2pRPzJiaILz		MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD60PEDPxE1w	NYTPd2ozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O\|Y2QTB7PD;hQi=>
MCF7	Mlu4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUC3NkBpenN?		MnLFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzIN88UU4>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
U87MG	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnjoO\|IhcHK\|		NXy3VmJNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU43PCEQvF2u	Ml[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
A549	M4TOe2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXq3NkBpenN?		NYLySGl5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyMlA4KM7:TT6=	M3TtdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
HeLa	NIfySYlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYW3NkBpenN?		M323UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iND6zOEDPxE1w	NUCyeYtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O\|Y2QTB7PD;hQi=>
HCT116	MX7GeY5kfGmxbjDhd5NigQ>?	NYDDV5pqOTBidV2=	MUGxJIhz		NYT3OIpSUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiQXv0JJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	NH\ZRYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
A2058 melanoma	MmC1R4VtdCCleXPs[UBie3OjeR?=	MUG1JJVO	M2\tcVI1KGi{cx?=		MkPMR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gRVIxPThibXXsZY5wdWFiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KFO3YlexJJBp[XOnIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCjbnHsfZNqew>?	NX7SPZZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
A2058 melanoma	MlXBR4VtdCCleXPs[UBie3OjeR?=	M3HmS\|UhfU1?	MoLhNlQhcHK\|		NXLlfoZHS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hSTJyNUigcYVt[W6xbXGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgZZQhPSC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m\|	M{DrSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK5OVkzLz5{OEiyPVU6OjxxYU6=
SKOV3	MWPD[YxtKGO7Y3zlJIF{e2G7	M{LXNlIhfU1?	M3OzSVI1KGi{cx?=		NIfqUXJE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBUU0:YMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEAzKHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN?	MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
SKOV3	Mk\oR4VtdCCleXPs[UBie3OjeR?=	M1PBRVIhfU1?	NHPTWIwzPCCqcoO=		MmjYR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gV2tQXjNiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KFO3YlexJJBp[XOnIHH0JFIhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCjbnHsfZNqew>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh{OUW5Nkc,Ojh6Mkm1PVI9N2F-
MDA-MB-231	M1rtRmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVG3NkBpenN?		MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLki4JO69VS5?	NXqwSZVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNFc1OjlpPkK5NVA4PDJ7PD;hQi=>
PC3	MX;DfZRwfG:6aXPpeJkh[XO\|YYm=		NF;Kd4E4OiCqcoO=		MkXSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1MlM1KM7:TT6=	M1vGTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
T47D	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		MlWwO\|IhcHK\|		MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC2MlkzKM7:TT6=	MnzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEe0NlkoRjJ7MUC3OFI6RC:jPh?=
MCF7	NWDLfXEzS3m2b4TvfIlkcXS7IHHzd4F6		MmixO\|IhcHK\|		NVv0XoFQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTFwMEWg{txONg>?	M4DjTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
TC32	Mkn1dWhVWyCjc4PhfS=>				MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	NELOfmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NF:1doFyUFSVIHHzd4F6				MkHRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MVfxTHRUKGG\|c3H5				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	M{LWWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NEjtZ\|hyUFSVIHHzd4F6				NFrlSXFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M4nxNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	MYXxTHRUKGG\|c3H5				M{e3dJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NWjQUmsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NX7mcm1weUiWUzDhd5NigQ>?				Mn;5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	M1jP[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MYXxTHRUKGG\|c3H5				NFX4c4xyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NVzOW29kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	M17LbpFJXFNiYYPzZZk>				MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NHW5NVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NW\FRnRFeUiWUzDhd5NigQ>?				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MWXxTHRUKGG\|c3H5				Mk[wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NUTJTmVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MXzxTHRUKGG\|c3H5				MlfQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MmTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MXnxTHRUKGG\|c3H5				M1;ZZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	M3iwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	M{nqPJFJXFNiYYPzZZk>				NGfyeVRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	M2mycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NGG3fnJyUFSVIHHzd4F6				MlPWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	M2Wwe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	MWDxTHRUKGG\|c3H5				MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	MnT0dWhVWyCjc4PhfS=>				MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	NETpOpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	NY\idpBLeUiWUzDhd5NigQ>?				M4TZUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	NVuzUJJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	NVvvcoRLeUiWUzDhd5NigQ>?				M2HPPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NV:2[YxTeUiWUzDhd5NigQ>?				MmrqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	M4nyXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MUDxTHRUKGG\|c3H5				M{TzbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NVTjSmt{eUiWUzDhd5NigQ>?				M{Lp[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NHezbXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	M3\qS5FJXFNiYYPzZZk>				M1XFcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M2P1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M1ruVZFJXFNiYYPzZZk>				NWX1foZzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NVuzfIFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	NIr2bYlyUFSVIHHzd4F6				NFzHb\|FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	M2fa[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NIjQPGFyUFSVIHHzd4F6				MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	NIjydmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MoP3dWhVWyCjc4PhfS=>				MmHpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	NEnNPWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	MYfxTHRUKGG\|c3H5				Mm\1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	Mnm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
insect	NGXUNZRHfW6ldHnvckBie3OjeR?=				NV7odlRMUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDIbZMufGGpZ3XkJJA5PWGucHjhM5AyOTCjbIDoZUBGPTR3SzDteZRidnRiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyxiSVO1NEA:KDBwMEGxJO69VS5?	NYHIdXF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
insect	M1rQfWZ2dmO2aX;uJIF{e2G7				NILuZlFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFjpd{11[WepZXSgdFg2[WyyaHGvdFEyOGGucHjhJGU2PDKNIH31eIFvfCCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{NCCLQ{WwJF0hOC5yMkmg{txONg>?	NG\WfFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
Sf21	M1PoTGZ2dmO2aX;uJIF{e2G7		MnzMNUBpeg>?		M1L3[GlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscE1t\W6pdHigUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCyMUGw[IVtfGFxcnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigdFg2[WyyaHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEhcW6\|ZXP0JINmdGy\|IIXzbY5oKFCLUEKgZZMhe3Wkc4TyZZRmKG2nYYP1doVlKGGodHXyJFEhcHJiYomgRYxmgGF4M{OgWJJi[2W{LXLhd4VlKG[udX;y[ZNk\W6lZTDwc4xieixiSVO1NEA:KDBwMUK1JO69VS5?	NYfVR2gyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
MCF7	M3\ifWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NF60fY04OiCqcoO=		MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiaHHyZo9zcW6pIGDJT\|NESSCHNUS1T{BufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNlA3KM7:TT6=	M1HBUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
Sf21	MorGSpVv[3Srb36gZZN{[Xl?		Mn3YNUBpeg>?		M4HOeWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscE1t\W6pdHigUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCyMUGwZoV1[S:{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDwPFVidHCqYTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBqdnOnY4SgZ4VtdHNidYPpcochWEmSMjDhd{B{fWK\|dILheIUhdWWjc4Xy[YQh[W[2ZYKgNUBpeiCkeTDBcIV5[TZ\|MzDUdoFk\XJvYnHz[YQh\my3b4Lld4NmdmOnIIDvcIFzcSxiSVO1NEA:KDBwMkO0JO69VS5?	M4Cxe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
T47D	NIm4emRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2rXfVczKGi{cx?=		NIi0Wm5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGS0O2Qh[2WubIOgbIFz[m:{aX7nJHBKO0uFQTDINVA1P1JibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ6NjFOwG0v	M4HWVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
PC3	NVvNdoRITnWwY4Tpc44h[XO\|YYm=		MlKxNkBpenN?		MWDJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bu\WG\|dYLl[EBi\nSncjCyJIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlM3PSEQvF2u	NGO5TXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
HT-29	M{[1N2NmdGxiY4njcIUh[XO\|YYm=	M1;KNlAvOTFzIITvJFMhfU1?	M{OwZlI1KGi{cx?=		MnzjR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTHQuOjliY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNE4yOTFidH:gN{B2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgQ>?	MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
A2058	M4LSVWZ2dmO2aX;uJIF{e2G7		MVuxJIhz		NHLZcIdKdmirYnn0bY9vKG:oIGTPVmMzKGmwIHj1cYFvKEF{MEW4JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFCNQj;Bb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFAvPDF4IN88UU4>	NG\vcoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO1PVAxOyd-M{CzOVkxODN:L3G+
A2058	MlO4SpVv[3Srb36gZZN{[Xl?		MmrCNUBpeg>?		MXTJcohq[mm2aX;uJI9nKFSRUlOxJIlvKGi3bXHuJGEzODV6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJHM3KHCqb4PwbI9zgWyjdHnvckBifCCVZYKyN\|UwOjN4IHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|LDDJR\|UxKD1iMD61OVMh\|ryPLh?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN3OUCwN{c,OzB\|NUmwNFM9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT (T308) / p-AKT (S473) / AKT; PubMed: 27283525 J Neurooncol Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation. p-FOXO3a (S253) / FOXO3a; PubMed: 28036259 Oncotarget Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control. Nuclear NF-κB p65 / NF-κB p65; PubMed: 26673665 Cell Death Dis Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. p-ERK / ERK / LC3; PubMed: 27572309 Oncotarget The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins. p-STAT3 / STAT3 / p-ERK / ERK / p-S6; PubMed: 29928341 Oncol Lett Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h. p-MET / MET; PubMed: 29928341 Oncol Lett The expression of phosphorylated or total forms of MET protein was analyzed by western blotting.	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a; PubMed: 28036259 Oncotarget Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.	28036259
Growth inhibition assay	Cell viability; PubMed: 26673665 Cell Death Dis Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).	26673665

体内研究

BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。^[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。^[2]

激酶实验：^[2]	- 合并 PI3K 生化实验(ATP 消耗实验): BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：^[1]	- 合并 Cell lines: A2780细胞 Concentrations: 0-6.6 μM Incubation Time: 3天 Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔10³个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37^oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠 Dosages: ~60 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

- 合并

溶解度 (25°C)

体外	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Buparlisib (BKM120) SDF

分子量	410.39
化学式	C₁₈H₂₁F₃N₆O₂
CAS号	944396-07-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NVP-BKM120

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Not yet recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	July 31 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

选择性强的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
选择性强的PI3K抑制剂

TGX-221 : p110β-specific, IC50=5 nM.
活性最高的PI3K抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

研究领域

产品类型

定制您的化合物库

Buparlisib (BKM120)

客户使用Selleck生产的Buparlisib (BKM120)发表文献203篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Buparlisib (BKM120) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品